News und Analysen
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![EQS-News: Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
EQS-News: Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
EQS-News: Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Evolva publishes timeline of the Reverse Stock Split](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Evolva publishes timeline of the Reverse Stock Split
Evolva publishes timeline of the Reverse Stock Split
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![EQS-Adhoc: BB Biotech AG publishes its interim report](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
![EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
![Lonza Increases Straight Bond by CHF 150 Million](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lonza Increases Straight Bond by CHF 150 Million
Lonza Increases Straight Bond by CHF 150 Million
![EQS-Adhoc: M1 Kliniken AG decides to start share buyback](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
![EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
![EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2022](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2022
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2022
![Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: First-quarter results 2023 of Sartorius Stedim Biotech
![EQS-News: Abivax reports 2022 financial results and operations update](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-News: Abivax reports 2022 financial results and operations update
EQS-News: Abivax reports 2022 financial results and operations update
![Annual General Meeting – Shareholders approve all proposals of the Board of Directors](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Annual General Meeting – Shareholders approve all proposals of the Board of Directors
Annual General Meeting – Shareholders approve all proposals of the Board of Directors
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer
EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer
![Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
![Convatec Group PLC: Scrip Dividend - Calculation Price](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Convatec Group PLC: Scrip Dividend - Calculation Price
Convatec Group PLC: Scrip Dividend - Calculation Price
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100